Biotech 2050 Podcast Podcast Por Biotech 2050 arte de portada

Biotech 2050 Podcast

Biotech 2050 Podcast

De: Biotech 2050
Escúchala gratis

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.All rights reserved Ciencia
Episodios
  • Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

    Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics
    Mar 6 2026
    Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM 2026 in San Francisco, host Alok Tayi speaks with Cary Claiborne, CEO of Adial Pharmaceuticals, about a new precision-medicine approach to tackling one of the world’s most widespread and undertreated conditions: alcohol use disorder. Cary shares the personal and professional journey that brought him into addiction medicine—from a career in finance at global corporations to helping take pioneering biotech companies public and ultimately leading Adial’s mission to address addiction through science. After losing a close family member to addiction, Cary became determined to focus his work on diseases where innovation could create meaningful societal impact. The discussion explores Adial’s genetically targeted therapy, designed to reduce alcohol cravings without requiring patients to stop drinking entirely. Cary explains how their repurposed low-dose therapy, paired with a simple cheek-swab diagnostic test, could help identify the patients most likely to benefit—bringing a precision-medicine framework to addiction treatment, an area that has seen little therapeutic innovation in more than two decades. Alok and Cary also examine the broader landscape of addiction science, the societal costs of untreated alcohol use disorder, and how AI-driven clinical simulations are helping design smarter Phase III trials. Looking ahead, Cary discusses how this scientific platform could expand into other impulse-driven conditions, including opioid addiction, gambling, and compulsive behaviors. It’s a compelling conversation about precision psychiatry, addiction medicine, and the future of neuropsychiatric drug development. Biography: Cary Claiborne was named Chief Executive Officer of Adial Pharmaceuticals in August 2022 after previously being appointed Chief Operating Officer in December 2021 and being named to the Board of Directors. Mr. Claiborne previously served as Chief Financial Officer (CFO) and board member of Indivior PLC, a publicly traded specialty pharmaceutical company developing medicines to treat addiction and serious mental illnesses. Among his accomplishments, Mr. Claiborne led the company’s spin off from its then parent company, Reckitt Benckiser, to become an independent, listed company. While at Indivior, he established and oversaw corporate reporting, internal audit, tax, treasury, external audit, and information technology. Prior to joining Indivior, Mr. Claiborne served as the CFO of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, which was later sold to Mallinckrodt. Before joining Sucampo, Mr. Claiborne served as CFO and Corporate Secretary of Osiris Therapeutics, Inc., and oversaw corporate finance during the company’s initial public offering. He graduated from Rutgers University with a B.A. in Business Administration and from Villanova University with an M.B.A. and was a National Association of Corporate Directors (NACD) Governance Fellow.
    Más Menos
    14 m
  • Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

    Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders
    Mar 5 2026
    Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a powerful conversation at the intersection of biotech innovation, leadership, and personal transformation. Sheila shares the unconventional journey that led her from academic medicine to the forefront of biotechnology—spanning roles at Genentech and Bristol Myers Squibb, founding companies, serving on boards, and recently helping guide Ventus Therapeutics through its acquisition by Lilly. Along the way, she reflects on the lessons she learned building drugs, scaling companies, and navigating the evolving biotech deal environment. The discussion then turns deeply personal as Sheila explores the ideas behind her book “The Mirror Effect,” revealing how self-awareness, supportive networks, and authentic leadership can transform careers—especially for women and underrepresented leaders in science. From overcoming imposter syndrome to building the “CEO Sisterhood” network of women biotech leaders, Sheila shares hard-earned insights on navigating power, culture, and identity in high-stakes industries. For founders, investors, and leaders alike, this episode blends biotech strategy with deeply human lessons on resilience, purpose, and the power of believing in yourself. Biography: SHEILA GUJRATHI, MD, is a biotech entrepreneur, executive, and champion for under- represented leaders. Over the past 25 years, she’s had the privilege of developing life-changing medicines for patients with serious diseases while building and running private and public biotech companies—including some exciting exits. Today she’s a founder, chairwoman, board director, strategic advisor, and consultant to start-up companies and investment funds. Dr. Gujrathi was the co-founder and former CEO of Gossamer Bio and former Chief Medical Officer of Receptos. Her journey started at Northwestern University, where she earned both her M.D. and biomedical engineering degree, and took her from the halls of Harvard, UCSF, and Stanford to the corporate offices of Fortune 500 companies like McKinsey, Genentech, and Bristol-Myers Squibb. Dr. Gujrathi has earned multiple leadership awards, including AIMBE Fellow, BLOC100 Luminary, Healthcare Technology Report Top 25 Women Leaders in Biotechnology, Corporate Directors Forum Director of the Year, and Fiercest Women in Life Sciences. But what really lights her up is creating the inclusive environments she wished she’d had throughout her career. That’s why she co-founded the Biotech CEO Sisterhood, a group of trailblazing female CEOs—because we’re all better when we support each other.
    Más Menos
    40 m
  • Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

    Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms
    Feb 11 2026
    Synopsis: At the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could reshape medicine. Fred traces his journey from medical school in Brazil to consulting at BCG, venture capital, and ultimately founding multiple companies—sharing why following curiosity, not rigid career ladders, shaped his path. Fred dives deep into the bottlenecks holding back traditional CAR-T therapies—manufacturing complexity, cost, hospitalization, and toxicity—and explains how Artiva’s off-the-shelf NK-cell platform aims to change the paradigm. The discussion explores why rheumatoid arthritis became Artiva’s lead indication, how immune “resets” could redefine autoimmune care, and what’s ahead in 2026 as the company prepares registrational trials and expands its basket studies across lupus, myositis, scleroderma, and more. The episode closes with rapid-fire takes on AI in drug development, China’s accelerating biotech engine, rare disease trial models, and the strategic principles founders should follow when choosing indications and building durable platforms. Biography: Fred Aslan, M.D., has a 20-year track record as an executive and investor in the life sciences industry. He was most recently President and CBO at Vividion Therapeutics, where he was responsible for business development, finance, alliance and project management, and operations. Dr. Aslan had the opportunity to lead Vividion’s Series B financing and $135M-upfront collaboration with Roche. Prior to Vividion, Dr. Aslan had a 12-year affiliation with Venrock. Initially he was an investor from 2006 to 2013, when he cofounded and served as a board member of Receptos Pharmaceuticals (acquired by Celgene for more than $7 billion). Dr. Aslan led Venrock’s investment in Zeltiq (acquired by Allergan for more than $2 billion) and was involved in the early formation of Fate Therapeutics. Subsequently as an entrepreneur from 2013 to 2018, he was CEO of Adavium Medical, a Brazilian medical device company, which he grew from zero to 350 employees, sales of over US$40 million, and fully integrated R&D, manufacturing, and commercial capabilities. Prior to Venrock, Dr. Aslan was Director of Business Development and Head of Investor Relations for CuraGen, a Nasdaq-listed oncology-focused biotech company. Prior to CuraGen, he was a consultant at Boston Consulting Group (BCG). Dr. Aslan holds a B.S. in biology from Duke University, an M.D. from Yale School of Medicine, and an MBA from Harvard Business School.
    Más Menos
    25 m
Todavía no hay opiniones